Alcohol Use Disorder

Marc Potenza, PhD, MD, explores the impact of online social activity on ADHD symptoms in adolescents, revealing significant gender differences in brain development and attention.

GLP-1 receptor agonists emerge as potential game-changers in psychiatric treatment, targeting mental disorders and improving cognitive function.

Brigitte Robertson, MD, shares information on innovative, genetically targeted treatments for alcohol use disorder, aiming to personalize care and improve patient outcomes.

Adial Pharmaceuticals advances its treatment for alcohol use disorder, AD04, with FDA meetings and promising genetic insights for targeted therapy.

BLP-003, currently being evaluated for treatment-resistant depression and alcohol use disorder, today announced their global phase 2b clinical trial has completed patient enrollment.

The FDA gave positive feedback to Adial Pharmaceuticals regarding its proposed in vitro bridging strategy for the phase 3 formulation of AD04.

A new patent was issued for Adial Pharmaceuticals’ identification of patients with specific genetic markers linked to substance use disorders and treatment with AD04.

At the beginning of this year, US Surgeon General Vivek H. Murthy, MD, MBA, issued a health advisory warning about the link between alcohol use and the risk of cancer. Learn more about its implications for psychiatry here.

Check out the pipeline updates from January!

Here are highlights from this week in Psychiatric Times, including FDA news and a look back at Psychiatric Times through the years.

New positive results of a pharmacokinetics study of AD04 for alcohol use disorder confirms the near micro-dosing regimen planned for upcoming trials.

Check out new positive topline results from the open-label phase 2A study of BPL-003 in participants with moderate-to-severe alcohol use disorder.

Here are highlights from this week in Psychiatric Times, including FDA approvals and conference coverage.

Joseph Volpicelli MD, PhD, reflects on 40 years of advancements in addiction treatment, from overcoming stigma to integrating evidence-based therapies like naltrexone.

Chris Schenewerk, MD, shares how his battle with alcohol addiction transformed his understanding of addiction treatment.

How can personalized care, addressing comorbidities, and focusing on gradual improvement help increase treatment success for alcohol use disorder?

An observational cohort study found patients at less risk of hospitalization for alcohol use disorder when also being treated with a GLP-1 agonist anti-diabetic/obesity agent.

Check out new results of a pharmacokinetics study of AD04, an investigational therapeutic agent for the treatment of alcohol use disorder in patients with heavy drinking.

Enter your email to check out this complicated case!

In this CME article, learn how best to provide end-of-life care to patients with psychiatric disorders.

The FDA instead issued a CRL for MDMA-assisted psychotherapy for PTSD, requesting an additional phase 3 trial to examine safety and efficacy. Other psychedelic compounds are proceeding with trials for psychiatric conditions. Learn more here.

Learn more about the latest research related to 9/11 trauma and other psychiatric comorbidities.

In this CME article, learn more about how to assess the impact of alcohol and cannabis use on anxiety treatment outcomes, recognizing potential adverse effects and interactions.

Social media is here to stay, and its use must be a consideration in the treatment of psychiatric conditions, particularly substance use disorder and alcohol use disorder.

What is new in research on alcohol use disorder?